cd66 (cea)(cea31) (Biotium)
Biotium is a verified supplier 
Biotium manufactures this product 
99
Structured Review
Biotium
cd66 (cea)(cea31)
Cd66 (Cea)(Cea31), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 64 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd66+(cea)(cea31)/CD66+(CEA)(CEA31)/custom%40bnc040670-100%4042457045
Average 99 stars, based on 64 article reviews
Cd66 (Cea)(Cea31), supplied by Biotium, used in various techniques. Bioz Stars score: 99/100, based on 64 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd66+(cea)(cea31)/CD66+(CEA)(CEA31)/custom%40bnc040670-100%4042457045
Average 99 stars, based on 64 article reviews
cd66 (cea)(cea31) - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Immunohistochemistry:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Staining:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Expressing:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Biomarker Discovery:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Immunohistochemical staining:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Fluorescence:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a In Situ Hybridization:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Hybridization:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a In Situ:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Wilms Tumor Assay:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a Fluorescence In Situ Hybridization:Article Title: Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors Article Snippet: 026.107697 ). CEA+ tumors were defined as those with ≥20% of tumor cell membranes staining with at least moderate intensity by immunohistochemistry (IHC). Staining for CEA was performed locally with a |